關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。

搜尋結果Search Result

符合「OT」新聞搜尋結果， 共 36 篇 ，以下為 1 - 24 篇 訂閱此列表，掌握最新動態
Global Business News
NEXCOM Brings Expanded Edge, Security, and Quantum-Resistant Innovations to MWC Barcelona 2026

TAIPEI, Jan. 13, 2026 /PRNewswire/ -- NEXCOM, a leading supplier of network appliances, will join MWC Barcelona 2026 presenting a broadened portfolio designed to support future-ready networks across telecom, enterprise, and industrial environments. As one of the selected innovators featured in the Taiwan Pavilion—supported by the Industrial Development Bureau, MOEA—NEXCOM brings breakthrough technologies designed and manufactured in Taiwan to MWC Barcelona at booth 5A61 (Hall 5). NEXCOM brings expanded edge, security, and quantum-resistant innovations to MWC Barcelona 2026. Must see at booth 5A61 (Taiwan Pavilion): broadened portfolio of solutions addressing today’s most pressing challenges in secure, synchronized, and resilient networking, built to solve real-world problems across telecom, enterprise, and industrial environments. Visitors will be able to explore NEXCOM's latest innovations designed to address emerging challenges in secure, synchronized, and resilient networking. Key highlights include: Post-Quantum Cryptography (PQC)Platforms designed to integrate PQC-ready frameworks that aim to help customers strengthen long-term protection as operators prepare for quantum-era threats. Time-Sensitive Networking (TSN) Activation KitTotal solution to simplify configuration, accelerate deployment, and enable precise, real-time synchronization across smart warehouse automation, production logistics, and industrial edge networks. NEXBOOT Dual-Layer Failover MechanismA combined hardware-level redundancy and firmware-level self-recovery approach to reduce costly field returns and maintenance time — with minimal effort. Compact,Value-Driven Network AppliancesSD-Edge, security, and uCPE platforms engineered for strong performance, efficient power usage, and rich functionality within smaller footprints. Collaborative Partner SolutionsEcosystem-integrated solutions demonstrating how NEXCOM hardware aligns with partner technologies to accelerate the rollout of advanced networking, cybersecurity, and edge-AI applications. NEXCOM invites industry professionals to secure a meeting slot and explore collaboration possibilities. NEXCOM experts will be available throughout the event at the Taiwan Pavilion booth 5A61 (Hall 5) to guide through latest network and communication platforms and engage in focused solution discussions. NEXCOM will share additional technology highlights and introduce new products in the coming press announcements. Stay tuned for more updates. About NEXCOM Founded in 1992 and headquartered in Taipei, Taiwan, NEXCOM is shaping the future of AI-powered networking with its software-defined solutions. Through its Network and Communication Solutions (NCS) unit, NEXCOM delivers cutting-edge platforms for Cybersecurity, OT Security, SD-WAN, SASE, Load Balancing, 5G uCPE, edge AI, and more. NCS specializes in professional design and manufacturing services, enabling reliable and scalable network infrastructures for businesses of all sizes. With a focus on innovation, NEXCOM's solutions empower customers worldwide to build resilient, high-performance networks tailored to the demands of tomorrow's connectivity challenges.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 109 加入收藏 :
LEGO Pokémon Collaboration
Global Business News
Can You Catch and Build Them All? The LEGO Group Reveals First-Ever LEGO Pokémon Sets and Trainer Challenge

BILLUND, Denmark, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Today, the LEGO Group and The Pokémon Company International are unveiling the first ever collection of highly anticipated LEGO® Pokémon™ sets. Based on some of the most iconic Pokémon from the brand’s 30-year history, the first LEGO Pokémon sets allow fans to build and display their favourite Pokémon in LEGO brick form when they launch on 27 February 2026. This exciting collaboration brings together two beloved worlds, inviting fans everywhere to continue their Pokémon Trainer journey, brick by brick. The launch of the first three sets sees five fan favourite Pokémon - Pikachu, Eevee, Venusaur, Charizard and Blastoise - recreated in LEGO brick form, giving builders the opportunity to bring their adventures to life, one brick at a time. A set truly worthy of one of the most recognisable Pokémon – the LEGO® Pokémon™ Pikachu and Poké Ball. The set lets fans recreate one of the most iconic scenes from the franchise: Pikachu jumping out of the Poké Ball ready for battle. The brick-built Pikachu showcases this beloved Pokémon in a dynamic pose, leaping out from a Poké Ball. The 2,050-piece set features a black lightning rod shaped base, with lightning energy emitting from the Poké Ball as Pikachu exits, ready for action. Key easter eggs include a “25” displayed on the base, signifying Pikachu’s Pokédex number. Celebrating the iconic Electric-type Pokémon, fans will be able to pose the build in a dynamic battle stance launching from the opened Poké Ball, as well as in a seated pose, with a closed Poké Ball. The truly epic LEGO® Pokémon™ Venusaur, Charizard and Blastoise set brings three of the most celebrated Pokémon to fans in one of the LEGO Group’s largest ever display sets. Made up of over 6,838-pieces, the set features three Kanto first partner Pokémon evolutions, for the first time, in LEGO brick form. Each of the three figures faithfully capture the original designs with remarkable authenticity and with their own unique articulation. These Pokémon can be displayed individually or together on the action base, which hides easter-eggs for fans to discover as they build. The base features design details inspired by each of the featured Pokémon’s biomes, adding further depth to the display. Celebrate Eevee’s irresistible charm with LEGO® Pokémon™ Eevee, a 587-piece set that brings the cherished Pokémon to life in dynamic detail. Eevee’s expressive face, movable tail, head and limbs allow builders to pose the fan-favourite, either at rest or ready to jump into action. With the Build Together app, this set presents fans with the ability to build together with friends and family. Julia Goldin, Chief Product & Marketing Officer of the LEGO Group, said: “Bringing the world of Pokémon to life in LEGO bricks is both an exciting opportunity and a great responsibility. We’ve worked to combine our worlds in a way that truly celebrates the creativity, adventure, and wonder that Pokémon represents. This partnership opens up a whole new range of possibilities for Trainers and builders alike, and we can’t wait for fans to experience these new LEGO Pokémon sets.” “As a lifelong Pokémon fan, it's been an incredible honour to help bring these Pokémon to life in LEGO brick form for the first time,” said Siddharth Muthyala, Design Director on LEGO Pokémon. “Pokémon has inspired generations of fans around the world, so our team approached the design of these sets with immense care and passion, ensuring every detail and pose truly celebrates what makes these characters so beloved. I hope fans will love building them, as much as we did designing them.” Gaku Susai, Chief Product and Experience Officer at The Pokémon Company International, adds: “Pokémon has always inspired discovery and connection and partnering with the LEGO Group brings those qualities together with creativity and imagination into a new form. By combining Pokémon’s sense of adventure with the thoughtful design and attention to detail of the LEGO Group, we’re giving fans the chance to build, play, and tell their own stories in ways they’ve never experienced before - something we’re thrilled to see come to life.” Scavenger Hunt – Find & Catch Them All!Between 12 January – 27 February LEGO Pokémon fans will be able to look for hidden LEGO Pokémon clues across digital channels. They will be challenged to find clues hidden throughout LEGO digital content and Pokémon digital content, to unlock exciting rewards and the chance to win The Grand Prize: experiencing PokémonXP and the 2026 Pokémon World Championships in San Francisco, including access to Championship Sunday at the Chase Center, as well as all three new LEGO Pokémon sets. For more information around the LEGO Pokémon Scavenger Hunt, fans can visit: LEGO.com/Pokémon Accompanying photographyTo celebrate the partnership, the LEGO Group has commissioned photography that captures the five Pokémon in five real-world settings across the world. Each location was chosen to reflect the unique traits and personalities of the Pokémon, blending their characters with breathtaking landscapes.Gift with Purchase DetailsBetween 27 February – 8 March 2026, shoppers will receive a LEGO Pokémon Kanto Region Badge Collection (40892) as a gift with purchase when purchasing the LEGO Pokémon Venusaur, Charizard and Blastoise set (72153) at LEGO.com and LEGO branded stores while stocks last. The new LEGO Pokémon sets will be available for pre-order starting today via LEGO.com/Pokemon, with immediate purchase available on LEGO.com, LEGO Stores and in selected retailers around the world, starting 27 February 2026. Notes to Editor For more information, please contact: media@LEGO.com. About the LEGO GroupThe LEGO Group’s mission is to inspire and develop the builders of tomorrow through the power of play. The LEGO System in Play, with its foundation in LEGO bricks, allows children and fans to build and rebuild anything they can imagine. The LEGO Group was founded in Billund, Denmark in 1932 by Ole Kirk Kristiansen, its name derived from the two Danish words LEg GOdt, which mean “Play Well”. Today, the LEGO Group remains a family-owned company headquartered in Billund. However, its products are now sold in more than 120 countries worldwide. For more news from the LEGO Group, information about our financial performance and responsibility engagement, please visit www.LEGO.com/aboutus. About Pokémon The Pokémon Company International, a subsidiary of The Pokémon Company in Japan, manages the property outside of Asia and is responsible for brand management, licensing, marketing, the Pokémon Trading Card Game, the animated TV series, home entertainment and the official Pokémon website. Pokémon was launched in Japan in 1996 and today is one of the most popular children’s entertainment properties in the world. For more information, please visit www.pokemon.com Photos accompanying this announcement are available at:  https://www.globenewswire.com/NewsRoom/AttachmentNg/410f382f-28ad-4cbf-b17d-47ea6c0880bf https://www.globenewswire.com/NewsRoom/AttachmentNg/a470b2f7-0faa-4993-b507-8df28fbec516 https://www.globenewswire.com/NewsRoom/AttachmentNg/d4ff7be3-dc9f-44fa-aebd-499ad77e5d84 https://www.globenewswire.com/NewsRoom/AttachmentNg/eaf460da-61ba-4f45-bb23-342c9b090b76

文章來源 : Notified 發表時間 : 瀏覽次數 : 151 加入收藏 :
Zymeworks Inc.
Global Business News
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Investment industry veteran Mr. Brian Cherry appointed to Board of Directors Dr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive Vice President and Chief Operating Officer Five new Vice Presidents appointed, underscoring our commitment to leadership development VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced appointments, promotions, retirements, and reductions to its leadership team intended to strengthen the capabilities and experience of the organization. These updates are designed to align key leadership roles with the Company’s corporate strategy announced in November. “At Zymeworks, we recognize that our greatest asset is our people. Ensuring that we continue to have the right set of key skills and experience within our Board of Directors and leadership team is critical for successful execution of our current strategy and driving long-term shareholder value. Elevating talented individuals at Zymeworks recognizes their strong performance for the Company, our continued confidence in their abilities and the emphasis we place on cultivating leaders from within,” said Kenneth Galbraith, Chair, Chief Executive Officer, and Acting Chief Financial Officer of Zymeworks. Board of Directors Strengthened to Support Future Strategy Brian Cherry has been appointed to the Board effective January 12, 2026 to bring the current Board to nine directors. Mr. Cherry has spent more than 25 years investing in and helping build businesses across a wide range of industries including healthcare, industrials, business services, financial services, and consumer products. He has led buyout and growth equity investments in companies totaling over $25 billion in enterprise value. Previously, Mr. Cherry was a Managing Partner at Oak Hill Capital, a private equity firm. His board experience includes over a dozen private and public companies, the U.S. Air Force Academy Foundation, and the Undergraduate Financial Aid Leadership Council at the University of Pennsylvania. Mr. Cherry earned his BA from Princeton University and his MBA from The Wharton School at the University of Pennsylvania. Mr. Galbraith added, “Over the past year, we have taken deliberate steps to streamline the Board, reducing its size from twelve to nine directors, while ensuring that the collective skills and experience of the Board are well aligned to provide effective oversight of the Company’s new corporate strategy. Brian brings complementary expertise to the Board, particularly in capital allocation and strategic acquisitions, which we believe will support disciplined execution and long-term shareholder value creation.” Mr. Cherry is the fourth new director appointed to Zymeworks’ Board over the past twelve months, joining Mr. Oleg Nodelman, Mr. Greg Ciongoli, and Mr. Robert E. Landry. Leadership Appointments and Transitions Position Company for Next Phase of Growth Mr. Mark Hollywood has been promoted to Executive Vice President and Chief Operating Officer with expanded responsibilities beyond his current leadership of Technology and Manufacturing Operations, Quality, and Alliance/Program Management. Dr. Sabeen Mekan has been promoted to Senior Vice President and Chief Medical Officer (CMO) effective February 1, 2026, with overall responsibility for our clinical development, regulatory affairs, pharmacovigilance/patient safety, and clinical operations. Dr. Jeff Smith, our current CMO, will be retiring effective January 31, 2026, while continuing to provide services as an adviser for a transitional time period. Ms. Leone Patterson, our Chief Financial and Business Officer and Mr. Daniel Dex, General Counsel, will both be departing from their roles at Zymeworks during the first quarter of 2026. The Company has commenced a comprehensive search for a permanent Chief Financial Officer with the experience required to support the Company’s next phase of development. Mr. Galbraith has assumed the role of Acting Chief Financial Officer until a replacement is secured. In addition, the following individuals have been promoted or appointed to the leadership team: Ms. Laura O’Connor, Senior Vice President and Chief Human Resources Officer Ms. Bijal Desai, Senior Vice President, Finance Dr. Lindsey Foulkes, Senior Vice President, Corporate Development and Strategy Dr. Charles Chen, Vice President, Translational Sciences Ms. Shrinal Inamdar, Vice President, Investor Relations Ms. Diana Papove, Vice President, Corporate Communications Ms. Victoria Spencer, Vice President, Treasury and Tax Dr. Lingxing Zheng, Vice President, Regulatory Affairs “These outstanding individuals have consistently demonstrated exceptional leadership abilities, commitment to our vision, and a deep understanding of both our strategic objectives and our commitment to bringing meaningful medicines to patients worldwide,” stated Mr. Galbraith. “These leadership changes reflect the alignment of management resources to effectively execute against our strategic objectives in order to drive long-term shareholder value at Zymeworks.” Additional information on the background and experience of these individuals is available on the Company’s website at www.zymeworks.com. About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X. Cautionary Note Regarding Forward-Looking Statements This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ expectations regarding implementation of its strategic priorities and the anticipated benefits thereof; implementation of its evolving asset aggregation strategy, including existing and potential future royalty streams and existing and potential new partnerships; statements that relate to the expected contributions of personnel to Zymeworks’ strategic goals and long-term shareholder value; anticipated capital allocation strategy; industry opportunities for acquisition of new revenue streams or collaborations; the commercial potential of technology platforms and product candidates; Zymeworks’ early-stage pipeline and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; zanidatamab may not be successfully commercialized; Zymeworks’ evolution of its business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks’ business strategy may not deliver meaningful shareholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks’ assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. Investor inquiries:Shrinal InamdarVice President, Investor Relations(604) 678-1388ir@zymeworks.com  Media inquiries:Diana PapoveVice President, Corporate Communications(604) 678-1388media@zymeworks.com 

文章來源 : Notified 發表時間 : 瀏覽次數 : 80 加入收藏 :
Health-ISAC
Global Business News
Paul Chua Joins Health-ISAC® as Asia Pacific Operations Director

Chua will spearhead Health-ISAC’s expansion into the APAC region, enhancing cybersecurity and resilience in the global health sector SINGAPORE, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center (Health-ISAC) is pleased to announce the appointment of Paul Chua as its new Asia Pacific (APAC) Operations Director. In this pivotal role, Mr. Chua will oversee Health-ISAC’s operations across the APAC region, focusing on expanding the organization’s regional presence and fostering collaboration among member organizations. He will also be responsible for building and maintaining strategic partnerships with regional stakeholders, such as industry associations, government agencies, and law enforcement, to improve cybersecurity awareness and patient safety. Mr. Chua brings nearly 30 years of experience in managing IT and cybersecurity operations across the APAC region. Most recently, he served as the Greater Asia Cybersecurity Officer at Becton Dickinson (BD), where he led initiatives to secure IT, OT, and medical device products. His deep expertise in both the health and cybersecurity sectors makes him uniquely qualified to lead Health-ISAC’s mission in this diverse and rapidly evolving market. "We are thrilled to welcome Paul to the Health-ISAC team," said Denise Anderson, President and CEO of Health-ISAC. "His extensive background in the health sector, his experience as a participating Health-ISAC member and his proven track record of building strong networks across the APAC region will be invaluable as we continue to solidify our global commitment to securing the health sector". Errol Weiss, Chief Security Officer at Health-ISAC, added: "Cybersecurity is a team sport, and information sharing is at the heart of our collective defense. Having worked with Paul through his leadership at BD and his active role in APACMed, I have seen firsthand his commitment to health sector resilience. His deep technical background and ability to navigate complex regulatory environments across APAC will be critical as we expand our regional capabilities." A recognized thought leader, Mr. Chua is a frequent speaker at industry conferences and serves as an active member of APACMed, where he focuses on cybersecurity information sharing. He holds a Bachelor of Computer Engineering from Nanyang Technological University and a joint MBA from HKUST and Northwestern University’s Kellogg School of Management. He is also a certified cybersecurity professional with GCIH, CISSP, CCSP, and FIP credentials. "I am honored to join Health-ISAC and contribute to its mission of building a resilient health community," said Paul Chua. "I look forward to leveraging my experience to bring meaningful value to our members and enhance the collective security posture of the APAC health ecosystem". Health-ISAC invites the regional health community to meet Paul Chua and the expanding APAC operations team in person at the 2026 APAC Summit. The event will be held in Bali, providing a premier opportunity for stakeholders to share insights, discuss regional threats, and strengthen the collaborative network. For more information and to register, please visit: https://health-isac.org/summit-meeting/2026-apac/. ABOUT HEALTH-ISAC Health-ISAC (Health Information Sharing and Analysis Center) is a global, non-profit, member-driven organization where health sector stakeholders join a trusted community and forum for sharing timely, actionable, and relevant information. This information includes intelligence on cyber and physical security threats, as well as best practices and mitigation strategies to ensure operational resilience and patient safety. Media Inquiries: Mary Stratton, AVP of Marketing, contact@health-isac.org +1 321-593-1470 Connect with us: LinkedIn: https://www.linkedin.com/company/health-isac/ Twitter: https://twitter.com/HealthISAC

文章來源 : Notified 發表時間 : 瀏覽次數 : 161 加入收藏 :
AACSB International
其他商業
AACSB 就 2026 年商學教育全球標準展開公眾諮詢

佛羅里達州坦帕市, Jan. 11, 2026 (GLOBE NEWSWIRE) -- AACSB International 今日發佈其首份《商學教育全球標準》(Global Standards for Business Education) 及《2026 會計認證標準》(2026 Accounting Accreditation Standards) 的諮詢草案，邀請全球商學院、教職員、學生、僱主、高等教育協會及其他持份者提供意見。 全新《商學教育全球標準》乃修訂自 AACSB 備受推崇的認證標準，旨在為所有商學院提供參考，而不只限於已取得 AACSB 認證的學校。 這套標準提供獲全球認可的框架，任何商學院均可藉此指引策略發展、提升表現，並且向學員、僱主及高等教育界持份者展現出其成果及影響力。 適逢 AACSB 成立 110 週年，是次發佈正好體現該機構在促進全球商學教育質素及影響力方面與時並進的歷程。 AACSB International 主席兼行政總裁 Lily Bi 表示：「現今對商學教育的要求更勝以往，既要培育學員迎接經濟變化、創造啟迪實務的知識，亦要協助化解社會挑戰。 這些諮詢草案邀請全球各界攜手構建以價值觀為導向的現代實用標準框架，從而在多元的使命及環境中力求卓越。 我們鼓勵持份者審閱草案並踴躍表達意見，使最終標準反映商學與會計教育當下所需，亦能指引其未來發展方向。」 AACSB 在此時提出新標準，皆因商學教育正面臨越來越嚴格的審視及攀升的期望，包括要求更清晰的學習成果證明，課程、研究與社會影響之間亦必須更加緊密相連。 AACSB International 執行副總裁兼認證總監 Stephanie Bryant 指出：「《商學教育全球標準》的推出，彰顯 AACSB 作為全球標準制定者的地位，並推動商學教育生態系統蓬勃發展。」她指出，對院校而言，草案提供「富有彈性的清晰框架以展現質素」，並可「促進持續改善」。 全新《商學教育全球標準》及《2026 會計標準》旨在協助院校應對不斷演變的學員需求、勞動力中斷及迅速技術變革，同時保持一致的全球質素基準及持續改進。 諮詢草案重點內容 標準草案圍繞三個核心領域，強調以使命為本、以成果為重的質素： 策略管理：融貫策略、管治及資源，以奠定長遠質素及持續改進的基礎。 學員成就：提升對課程設計、學習成果保證及數碼靈敏度的要求。 影響力之路：提升學術影響力，促進學術及專業領域的互動參與。 這些標準追求兼容並蓄，配合各類院校模式及地區背景，同時為商學教育質素建構共通一致的全球語言。 了解更多 AACSB 將於 2026 年 1 月 12 日舉辦網絡研討會，概述諮詢草案中對商學與會計認證標準的關鍵修訂方向。 在此登記: https://www.aacsb.edu/events/2026/01/aacsb-business-and-accounting-standards-revisions-webinar 參與方式 AACSB 鼓勵持份者審閱其首份《商學教育全球標準》及《2026 會計認證標準》的諮詢草案，並於 2026 年 2 月 7 日前透過問卷調查提交意見。 各方建言將為修訂提供參考依據，以助最終確立 2026 年標準。 關於 AACSB AACSB International (AACSB) 自 1916 年成立以來，一直致力聯絡教育工作者、學員及商界，共同培育新世代優秀領袖。 AACSB 於全球擁有超過 2,000 個成員機構及 1,000 多間認證商學院，是世上規模最大的商學教育網絡。 AACSB 運用全球標準、認證系統及思維領導，凝聚各界參與、驅動創新，並加強商學教育的影響力。 aacsb.edumediarelations@aacsb.edu

文章來源 : Notified 發表時間 : 瀏覽次數 : 257 加入收藏 :
Dark Horse Consulting Group
其他商業
Bruder Consulting & Venture Group 將併入 Dark Horse Consulting Regenerative Medicine

加州核桃溪 和紐約, Jan. 10, 2026 (GLOBE NEWSWIRE) -- 領先的生物療法策略與營運諮詢公司 Dark Horse Consulting Group（「DHCG」或「該集團」）欣然宣佈收購 Bruder Consulting & Venture Group（「Bruder」或「BCVG」）一事。BCVG 是一間在生物科技與生物製藥界具有全球影響力的策略顧問及諮詢公司，憑著其專長而聲譽卓著，涵蓋骨科、傷口護理及整形與重建外科市場的生物製劑、裝置及組合產品之探索、開發、臨床設計與監管審批流程。 BCVG 現已成為 Dark Horse Consulting (DHC) 旗下部門，命名為 DHC Regenerative Medicine。 是次收購建立整合式諮詢服務生態系統，進一步鞏固 DHCG 以病人為本、加速生物療法開發與商業化的宗旨。 繼近期與 BioTechLogic 及 Converge Consulting 達成的策略擴展後，如今 BCVG 加入更是錦上添花，將集團的綜合實力版圖延伸至再生醫學、組織修復及生物材料等領域。 Bruder 的全球業務網絡，與 DHCG 作為全方位整合全球諮詢實體的定位相得益彰。 Dark Horse Consulting Group 創辦人兼行政總裁 Anthony Davies 博士表示：「歡迎 Bruder 以再生醫學專家的角色加入 Dark Horse 大家庭，這是本集團策略增長階段的另一個意義重大里程碑。 BCVG 在再生醫學界經驗豐富，使我們的整體專業實力更上一層樓，並提升我們為開發人員與投資者提供全面解決方案的能力，從而更迅速高效地推進療法發展，最終讓全球病人受益。」 BCVG 創辦人兼行政總裁 Scott P. Bruder 醫學及哲學博士補充：「通過與 DHCG 聯手合作，我們得以拓展核心團隊及顧問的專業能力，從而在開發過程的各個階段，發掘更多支援客戶合作夥伴的機會。 我們在再生醫學領域的專業知識，亦將為集團現有客戶帶來全面的附加價值及服務項目。」 在此交易中，BCVG 由 Goodwin Procter LLP 和 Edgemont Partners 代表， DHCG 則由 Fenwick & West LLP 代表。 關於 Dark Horse Consulting Group Dark Horse Consulting Group 是成立於 2014 年的全球諮詢機構，於北美、歐洲及亞太區均設有辦事處，以無可匹敵的專業實力為基石，致力推動細胞與基因療法的研發與應用進程。 自此，該集團的業務重心大幅擴展，其諮詢團隊的專業知識已涵蓋生物製藥領域的策略、營運、質素、監管事務、生產製造、建模、供應鏈、商業上市及業務優化。 DHCG 提供白手套客戶服務，此服務建基於嚴謹的科學與技術專長，為客戶提供從早期探索到商業上市的全程鼎力支援。 該集團由三大業務部門組成：DHC、BioTechLogic 及 Converge Consulting，而 BCVG 現為 DHC 旗下專門的再生醫學部門。 關於 Bruder Consulting & Venture Group Bruder Consulting & Venture Group 是一間全方位服務的策略顧問公司，其專長領域涵蓋骨科、傷口護理及整形與重建外科市場的生物製劑、裝置及組合產品之探索、開發、臨床設計與監管審批流程。 BCVG 的專家團隊在產品開發領域經驗豐富，已為全球逾 150 間企業完成超過 900 個項目，並在美國及海外主導或協助完成總值逾 20 億美元的授權、合併與收購交易。 傳媒查詢： contactus@darkhorseconsultinggroup.com +1 408-326-0303 內線： 209

文章來源 : Notified 發表時間 : 瀏覽次數 : 282 加入收藏 :
Attindas Hygiene Partners 透過關鍵收購擴展歐洲市場版圖
發表時間 :
開年 開運 開心 香港召集全球旅客共迎馬年 「國泰新春國際匯演之夜」閃耀大年初一 點亮全城連串新春節慶活動
發表時間 :
VCI Global’s World’s First NVIDIA Blackwell-Powered Enterprise AI GPU Lounge Becomes Operational, Introducing a New Asset-Light Model for Enterprise AI Infrastructure
發表時間 :
At the Yacht Club de Monaco a year of transition and innovation begins
發表時間 :
Open Campus 與中央邦政府及 Geeks of Gurukul 合作數碼化 5,000 萬份學術紀錄
發表時間 :
GDU 發佈 UAV-P300 無人機，全球首配人工智能光學與電子透霧功能
發表時間 :
Synchronoss 在 CES 2026 揭示個人雲端新布局，Capsyl 拓展多裝置與家庭應用
發表時間 :
香港首度主辦「亞洲50最佳餐廳」2026頒獎典禮
發表時間 :
Mark Your Calendar: Hong Kong to Host Asia’s 50 Best Restaurants 2026 after Historic Double Win
發表時間 :
VCI Global Secures Fully Funded 250MW “Green AI” Solar and 800MWH BESS Roadmap with Global Energy Titan Tianneng
發表時間 :
越南科技震撼全球
發表時間 :
Datavault AI 宣佈參與 2026 年消費電子展，向投資者報告聲學部門最新成果
發表時間 :
Snail Inc. 旗下核心知識產權年終參與熱度強勁，預示公司 2026 年發展氣勢向好
發表時間 :
為智慧工廠鋪路：ADI獲得CC-Link IE TSN認證
發表時間 :
VCI Global Reaffirms Oobit Transaction as Ecosystem Partners Target Completion of OOB Digital Treasury Infrastructure by Q1 2026
發表時間 :
斯洛文尼亞提升雪地運動、北歐式徑道及戶外探險樂趣迎冬季
發表時間 :
旅發局「香港跨年倒數」假中環地標呈獻音樂光影表演
發表時間 :
VCI Global Unveils 2026 “Sovereign RWA Ecosystem” Roadmap: Proprietary Exchange to Anchor Multi-Sector Asset Tokenization
發表時間 :
2026 年 1 月 13 日 (星期二) 農曆十一月廿五日
A12 藝術空間
TradeAsia 亞洲貿易網 | 開啟全球商機的專業 B2B 貿易平台 Web Builder 智慧型網站大師 | 網站建置的領導品牌
Rubber Seals, Silicone Rubber Maker | Chung Ta Rubber Solution Industrial Co., Ltd. Univer Adapter, Travel Adapter | Wonpro & Yang Ji Co., Ltd. Mini Fans, DC Blower | Risun Expanse Corp. Safety Goggles, Safety Spectacles OEM/ODM | Doris Industrial Co., Ltd. Electric Screwdriver | ASA Tools Enterprise Co. Ltd. Motorcycle Engine Cylinders, Crankshafts Manufacturer | Sheng-E MOTOR PARTS Co., Ltd. Kneader Mixer, Rubber Extruder Manufacturer | Well Shyang Machinery Co., Ltd. (WSM) TradeAsia 亞洲貿易網 | 開啟全球商機的專業 B2B 貿易平台 域名註冊 | 官網行銷第一步 打造您的專屬域名 - Asia Domain Bank 亞洲網址銀行 | AsianNet 亞洲網路 亞洲貿易展 Asian Trade Show | AsianNet 亞洲網路 Web Builder 智慧型網站大師 | 網站建置第一品牌 複成企業股份有限公司
首 頁 我的收藏 搜 尋 新聞發佈